Immedica Pharma becomes market authorisation holder for Ammonaps® and Ravicti® in Europe

news

Immedica Pharma AB announced today that Immedica became the Market Authorisation Holder (MAH) for Ammonaps® (Sodium phenylbutyrate) and Ravicti® (Glycerol phenylbutyrate), in 28 EU member countries, Norway and Iceland on 6 June 2019. Ammonaps® and Ravicti®, indicated for the treatment of Urea Cycle Disorders (UCD). In December 2018, Immedica acquired the rights for the products […]

New research links genetic defects in carbohydrate digestion to irritable bowel syndrome

news

“People with IBS often connect their symptoms to certain foods, particularly fermentable carbohydrates. We tested the hypothesis that genetic changes in the breakdown of disaccharides – small carbohydrates from sugars and starches – may be associated with increased risk of IBS” says corresponding author Mauro D’Amato from Karolinska Institutet.

Positive 2-year results with MD1003 in progressive MS

news

MedDay Reports Full Data from Pivotal Phase IIb/III MS-SPI / MS-ON Studies with MD1003 in Multiple Sclerosis at AAN First drug capable of reversing disease progression in patients with progressive MS Extension phase data demonstrate sustained efficacy up to 2 years Both studies support efficacy specifically in patients with not-active progressive MS Best effect size […]

GS-101 (aganirsen) in the Nordic countries

news

Medical Need announced today that it has entered into an exclusive supply and distribution agreement with Swiss company Gene Signal, relating to their product GS-101 (aganirsen) eye-drops, under development for the treatment of several ophthalmological conditions. The lead indication is for the treatment of corneal neovascularization, where one phase III trial has been completed, demonstrating […]

Medical Need part of Immedica Group and Laboratoires CTRS in Nordic collaboration

news

Medical Need part of Immedica Group announced today that it has entered into an exclusive supply and distribution agreement with the French company Laboratoires CTRS, regarding marketing and sale of CTRS portfolio of pharmaceuticals in the Nordic region. In 2013, CTRS received EU marketing authorization and orphan drug market exclusivity for its product Orphacol® (cholic […]

Additional results for MD1003 (Cerenday)

news

Press release: MedDay Reports Additional Positive Data of its Pivotal Phase III Study With MD1003 in Patients with Progressive Multiple Sclerosis   Improvement of Clinical Global Impression of change evaluated by the physician (CGI) and by the patient (SGI) at 12 months (p<0.0001 and p=0.0094 respectively) Data to be presented at The 1stCongress of the […]

Multi-drug resistant tuberculosis (MDR-TB)

news

Medical Need announces that the product GranuPAS® has been granted EU marketing authorization by the European Commission on April 7, 2014. The product contains para-aminosalicylic acid (PAS) in a gastro resistant coated granular formulation. PAS is used in the treatment of multi-drug resistant tuberculosis (MDR-TB) in combination with other anti-tuberculosis agents. The gastro-resistant formulation prevents […]

Chronic remitting pouchitis

news

Medical Need enters into a collaboration with Atlantic Pharmaceuticals on first-in-class therapy for inflammatory bowel disease Medical Need, Stockholm Sweden and Atlantic Pharmaceuticals Ltd, Cambridge UK, announced today that they have entered into an exclusive agreement relating to, Alicaforsen enema, in development for the treatment of inflammatory bowel disease (IBD). Under the agreement, Medical Need […]